All In Biotech

Drug Trial Radar · NCT05469360

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

A Randomized, Participant and Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of a Single Intrathecally Administered Dose of NIO752 to Lower Cerebrospinal Fluid Total Tau Levels in Participants With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

38

Actual

Start

Feb 23, 2023

Primary completion

Jul 30, 2026

Study completion Sep 24, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment

Interventions

  • NIO752Drug

    A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

  • NIO752Drug

    A single intrathecal (cerebrospinal) injection of NIO752 at dose B

  • Matching placeboDrug

    A single intrathecal injection of matching placebo

  • NIO752Drug

    Multiple intrathecal injections of NIO752 of Dose A

  • NIO752Drug

    Two intrathecal injections of NIO752 at dose C

  • NIO752Drug

    Single intrathecal injection of NIO752 at dose C

  • Matching placeboDrug

    Two intrathecal injections of matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in cerebrospinal total tau from baseline to Day 85Time frame: Baseline, Day 85

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Kuopio, Finland

  • Novartis Investigative Site

    Turku, Finland

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

  • Novartis Investigative Site

    Malmö, Sweden

  • Novartis Investigative Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.